Jamile Shammo, MD

Jamile M. Shammo, MD, is a professor of medicine (hematology and oncology), as well as the Dr. Marjorie C. Barnett – Dr. Hau C. Kwaan Professor at Northwestern University’s Feinberg School of Medicine

Articles

Dr Shammo on Future Research Investigating Combination Regimens in Myelofibrosis

April 17th 2025

Jamile M. Shammo, MD, discusses future directions for investigating JAK inhibitor–based combination regimens in transfusion-dependent myelofibrosis.

Taking Trial Data to the Clinic in MPN and CLL From ASH 2023: Drs Rogers, Brown, and Shammo

December 13th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Exploring the Future of MF Treatment

August 7th 2023

The panel closes their discussion by highlighting novel agents in the treatment of myeloproliferative neoplasms to look out for.

Symptom Monitoring in Patients with MF

August 7th 2023

The panel explains the standards for symptom assessment in patients with myelofibrosis and how often patients are monitored.

Considering Toxicities and Side Effects of JAK Inhibitors in Patients with MF

July 31st 2023

Abdulraheem Yacoub, MD, details the side effect profiles of the approved JAK inhibitors for myelofibrosis treatment.

Sequencing Therapies in Patients with MF

July 31st 2023

Dr Jamile Shammo discusses how to approach sequencing therapies in patients with myelofibrosis and Dr Raajit Rampal explains the potential of the JAK inhibitor momelotinib in the treatment of myelofibrosis.

Pacritinib and Fedratinib for the Treatment of MF

July 24th 2023

Raajit Rampal, MD, and Abdulraheem Yacoub, MD, review data on the use of pacritinib and fedratinib in patients with myelofibrosis.

COMFORT-I and COMFORT-II Data Review

July 24th 2023

Jamile Shammo, MD, comments the currently approved treatment options for patients with myelofibrosis and review data from the COMFORT-I and COMFORT-II trials, which evaluates the use of ruxolitinib in MF.

The Role of Transplant in the Treatment of Patients With MF

July 17th 2023

Dr Abdulraheem Yacoub explains allogeneic hematopoietic cell transplantation in myelofibrosis, the only known curative treatment modality.

Reviewing the Types of Myelofibrosis

July 17th 2023

The panel reviews the types of myelofibrosis, discusses how to risk stratify and explains the role of biomarker testing in patients with MF.

Ropeginterferon alfa-2b for the Treatment of PV

July 10th 2023

Dr Jamile Shammo reviews recent data on the treatment of patients with polycythemia vera with ropeginterferon.

Ruxolitinib for the Management of PV

July 10th 2023

Abdulraheem Yacoub, MD, reviews data from the RESPONSE and RESPONSE-2 trials on the use of ruxolitinib for the treatment of polycythemia vera.

Selecting a Frontline Therapy for Patients With PV

July 3rd 2023

Jamile Shammo, MD, explains how she decides on the most appropriate treatment option for a patient with polycythemia vera.

Current Treatment Landscape for Patients With PV

July 3rd 2023

Drs Rampal and Yacoub details the currently available treatment options and reviews the rationale for use in patients with PV.

Risk Assessment for Patients with Polycythemia Vera (PV)

June 26th 2023

Dr Jamile Shammo describes how risk is assessed for patients with polycythemia vera.

An Overview of Myeloproliferative Neoplasms (MPNs)

June 26th 2023

Experts provide an overview of myeloproliferative neoplasms, including the subtypes, process of diagnosis as well as reviewing the role of biomarkers.